Group 1 - The core viewpoint of the articles highlights the significant rise in the Shanghai and Shenzhen stock indices in 2025, driven by policy support, capital inflow, and sectoral benefits, with the Shanghai Composite Index reaching 3963.68 points and the Shenzhen Component Index at 13603.89 points as of December 26 [2] - The China Securities Regulatory Commission has implemented reforms such as the Sci-Tech Innovation Board and expanded Sci-Tech bonds to promote deep integration of technology and capital, resulting in 102 strategic emerging industry companies entering the A-share market in 2025 [2] - Northbound capital significantly increased its holdings in the electronics and communications sectors in Q3, with the electronics sector's market value rising by 67.78% quarter-on-quarter, contributing to the index's rise [2] Group 2 - Fund manager Zhao Qiang's investment strategy focuses on a high-quality stock selection system anchored by ROIC, emphasizing long-term value over short-term speculation [3] - Zhao Qiang's funds, such as Xinhua Strategy Selected Stock A, achieved returns of 78.52% in 2025, benefiting from a focus on high-growth sectors like communications and electronics, which saw returns of 81.7% and 45.9% respectively [2][3] - The Xinhua Preferred Dividend Mixed A fund has shown exceptional performance with a year-to-date return of 74.66% and a total return of 1243.24% since inception, attributed to Zhao Qiang's unique investment strategy and precise industry allocation [6] Group 3 - The Xinhua Trend Leading Mixed Fund also performed well, with a year-to-date return of 77.93% and a total return of 452.98% since inception, driven by a focus on technology innovation and high-quality companies [19] - Key holdings in the fund include Ding Tong Technology and Maiwei Bio, both of which have shown significant price increases, with Ding Tong Technology's stock price rising by 210% during the holding period [10][7] - The fund's strategy includes dynamic adjustments to the portfolio, increasing exposure to high-quality companies while avoiding high-volatility risks, enhancing the overall risk management of the portfolio [15][20] Group 4 - The investment philosophy emphasizes capturing structural opportunities in technology and high-end manufacturing sectors, with a focus on companies with ROIC exceeding 15% [6][7] - The fund manager's approach includes a diversified investment across different segments of the technology chain, such as chip design and equipment manufacturing, to mitigate concentration risk [15] - The strategy of "value as an anchor, trend as a sail" has proven effective in navigating the structural market conditions of 2025, providing a replicable reference model for long-term investors [31]

Group 1 - The core viewpoint of the articles highlights a significant surge in the Chinese innovative drug sector, with license-out transactions exceeding $130 billion, marking a year-on-year increase of over 150% and surpassing 50% of the global total for the first time [1] - The cash flow generated from business development (BD) and the IPO boom is providing ample funding for research and development, which is crucial for the industry's future growth [1] - Three main driving forces for the industry in 2026 are identified: commercialization realization, clinical data validation, and improvement of payment systems, which are expected to usher in a new era of "value realization" [1] Group 2 - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, which covers numerous innovative targets [2] - The ETF is expected to continue its valuation recovery trend under the catalysts of innovative drug exports and commercial insurance directories [2]

Group 1 - The A-share market experienced a collective rise on the first trading day of 2026, with significant gains in sectors such as medical services and CRO [1] - The Hong Kong Innovation Drug Index surged by 3.86%, with notable individual stock performances including Zhaoyan New Drug up 11.32% and Tigermed up 7.07% [1] - The Hong Kong Innovation Drug 50 ETF saw a 5.30% increase, with a cumulative rise of 67.18% over the past year as of December 31, 2025 [1] Group 2 - In 2025, China approved 76 innovative drugs for market entry, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total value of innovative drug licensing transactions in China exceeded $130 billion in 2025, with over 150 transactions, also a record high [1] - Open Source Securities highlighted the emergence of multiple doubling stocks in various pharmaceutical segments driven by innovation, particularly in chemical preparations, biological products, and CXO sectors [2] Group 3 - The Hong Kong Innovation Drug 50 ETF tracks the Hong Kong Innovation Drug Index, which has a current P/E ratio of 31.23, indicating it is at a historical low compared to the past three years [2] - The index includes leading companies such as WuXi Biologics and Innovent Biologics, with nearly 90% weight in biological products and chemical pharmaceuticals, facilitating efficient investment in the high-volatility Hong Kong innovation drug sector [2] - The fund has established off-market connection funds for investors to maintain focus on the sector [2]

2026年首个交易日，A股、港股喜迎开门红，其中，港股互联网、港股创新药、港股芯片硬科技的 表现尤为惊艳。热门ETF方面，重仓互联网龙头的港股互联网ETF（513770）跳空高开，强势大涨超4% 突破年线；高弹性港股通创新药ETF（520880）强势走高现涨逾4%；全市场首只聚焦"港股芯片"产业链 的港股信息技术ETF（159131）场内价格涨逾3.5%。 银河证券认为，2026年港股总体有望震荡上行。国内外货币政策宽松背景下，外资和南向资金均有 望继续保持净流入趋势。在加快科技创新、新一轮供给侧改革、扩大内需等利好政策带动下，港股上市 公司盈利水平有望实现实质性提升，市场将迎来盈利与估值均上涨的格局。行情主线方面，在"十五 五"时期科技自立自强水平大幅提高的目标下，科技创新将是港股投资的一大主线。港股科技估值修复 空间仍大，龙头业绩有望呈现高景气特征。中信证券表示，AI依然是港股互联网板块估值上行的核心 催化。 港股互联网ETF（513770）及其联接基金（017125）被动跟踪中证港股通互联网指数，重仓阿里巴 巴-W、腾讯控股、小米集团-W等互联网龙头，前10大持仓汇聚AI云计算、大模型+各领域AI应用公 ...

21世纪经济报道记者李域 2025年落下帷幕，公募基金成绩单出炉，主动权益基金交出了亮眼的业绩答卷。 翻开融通产业趋势的季报，超额收益来源清晰可见，AI、新消费与创新药。李进将其归结为一种"时代感"的投资。 "巨大的投资收益往往来源于需求大幅扩张、产业规模快速增长的领域。"李进表示，他的日常工作聚焦于追踪社会变迁与产业演进，着力寻找 存在阶段性市场效率缺失、需求尚未得到充分满足的行业。因此，他对成长性行业抱有更高关注度，对这些方向投入更多研究精力，并保持持 续紧密的跟踪。 李进于2023年3月开始担任基金经理，当时就将投资组合全面聚焦于人工智能方向。彼时，市场对该趋势仍存疑虑，但李进判断人工智能代表 一次重大的技术进步，其影响可能超越互联网。其核心依据源于ChatGPT所展现出的用户增长态势——用户量从零到一亿仅用时一个月，如此 高速的扩张历程前所未有。 在形成初步判断后，他开展了产业链验证。自2023年初起，通过调研，观察到光模块等环节出现"每周爆单"的现象，进一步印证了人工智能产 业的真实景气度，从而确立了该方向的配置决策。 2023年年中，他关注到家庭成员开始使用含有胶原蛋白成分的化妆品，由此切入对该细 ...

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced a significant rally, with leading stocks such as BeiGene and Innovent Biologics rising nearly 5% and over 5% respectively, indicating strong market interest in innovative pharmaceuticals [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) opened with a continuous rise, peaking at over 4% increase, with a trading volume of 258 million yuan, surpassing the previous trading day's total [1][8]. - Major stocks in the innovative drug sector, including BeiGene, Innovent Biologics, and CSPC Pharmaceutical Group, saw increases of nearly 5% and over 3% respectively, reflecting a positive market sentiment [1][7]. Group 2: Regulatory and Market Developments - The National Medical Products Administration reported that 76 innovative drugs were approved for market in China in 2025, significantly exceeding the 48 approved in 2024, marking a historical high [1][10]. - The total value of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [1][10]. Group 3: Investment Insights - Analysts from Zhongyou Securities suggest that the maturity of clinical data will be a key driver for the innovative drug market in 2026, with business development (BD) expected to enhance the competitiveness of domestic new drugs [3][10]. - The current period is viewed as an optimal configuration window for the Hong Kong Stock Connect innovative drug sector, following a three-month adjustment that began in September 2025 [3][10]. - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which boasts significant advantages such as comprehensive coverage of innovative drug companies and a high concentration of leading firms [3][10]. Group 4: ETF Composition - The top ten holdings in the Hong Kong Stock Connect innovative drug ETF account for over 72% of the total weight, highlighting the dominance of leading companies in the sector [4][11]. - Key constituents include BeiGene (11.51% weight), Innovent Biologics (10.19%), and China Biologic Products (9.47%), among others, indicating a strong representation of major players in the innovative drug market [4][11]. Group 5: Alternative Investment Options - For investors seeking exposure to innovative drugs while mitigating volatility, the unique A-share drug ETF (562050) is recommended, which focuses on the top 50 A-share pharmaceutical companies, balancing innovative drugs with traditional Chinese medicine [4][12].

Group 1 - The Hong Kong stock market's innovative drug concept stocks are experiencing a continuous rebound, with notable increases in share prices [1] - Specifically, Gilead Sciences-B has risen nearly 10%, while Zhaoyan New Drug has increased by over 8% [1] - Other companies such as Tigermed, Innovent Biologics, and CSPC Pharmaceutical Group have also seen their stock prices rise significantly [1]

Core Viewpoint - The article emphasizes the importance of technological advancement as a central theme for investment strategies, highlighting the need for adaptation in the face of evolving market dynamics and opportunities presented by AI and other technologies [4][6][10]. Group 1: Technological Progress and Investment Opportunities - Technological progress is increasingly recognized as a key driver of economic development, with traditional growth drivers showing signs of weakening [6]. - The investment landscape is shifting, with a focus on both early-stage technologies and established sectors, particularly in the context of the U.S. and China's differing market dynamics [7]. - The Chinese stock market is viewed as being in a favorable investment period, with significant potential for growth due to low global capital allocation compared to the U.S. [8]. Group 2: Multi-Asset and Multi-Strategy Approach - The company is transitioning towards a multi-asset and multi-strategy investment model to adapt to a prolonged low-interest-rate environment, aiming to enhance risk-return profiles through diversification [10]. - The team has been actively expanding its asset allocation and investment strategies since 2019, including increasing exposure to gold and U.S. equities during market downturns [10]. Group 3: AI and Quantitative Investment - The integration of AI and machine learning into investment strategies has transformed the approach to quantitative investment, with a significant portion of research now focused on these technologies [12]. - Products with clear risk-return characteristics are expected to have broad opportunities in the evolving market landscape [12][13]. Group 4: Structural Investment Opportunities - Despite market changes, there remain enduring business models that generate cash flow and shareholder returns, indicating that value investing continues to hold merit [14]. - The company is focusing on identifying undervalued opportunities in the market, particularly in sectors that may be experiencing temporary setbacks [14]. Group 5: Emerging Industries and Innovations - The company is particularly interested in sectors such as smart driving, robotics, and AI, which are expected to present significant growth opportunities as industries undergo rapid iterations [15][16]. - The evolution of the AI sector has exceeded expectations, with substantial investments being made to develop AI technologies that could reshape various industries [17]. Group 6: Healthcare and New Drug Development - The innovation in the pharmaceutical sector, particularly in China, is seen as a critical investment theme, with expectations for domestically developed drugs to achieve global recognition [18]. - The research approach has evolved to emphasize teamwork and cross-disciplinary collaboration, enhancing the effectiveness of investment strategies in the healthcare sector [18]. Group 7: Renewable Energy and Sustainability - The transition to green energy is gaining momentum, with significant penetration rates in traditional vehicles and power generation, indicating a robust investment landscape in renewable energy [19]. - The company is adapting its research methodology to focus on systemic changes within the renewable energy sector, identifying opportunities across the entire supply chain [19]. Group 8: Robotics and Automation - The advancements in robotics, particularly in human-like robots and automated driving, are expected to create substantial commercial value and investment opportunities [20]. - The potential for a large database to enhance robotic capabilities is highlighted as a key area for future development and investment [20].

Core Viewpoint - The chief A-share strategist at CITIC Securities, Qiu Xiang, predicts that the profit growth rate of A-share companies will exhibit a pattern of low growth followed by high growth in 2026 [1] Group 1: Market Phases - The market trend is expected to be influenced by the US-China trade agreement and the US midterm elections, divided into three phases: 1. From now until the trade agreement is finalized, the market's upward slope is expected to slow down 2. From the agreement's implementation to the end of the midterm elections, A-shares are likely to experience sustained growth in a stable external environment 3. After the midterm elections, uncertainties from external disturbances may increase sharply, prompting investors to refocus on domestic factors [1] Group 2: Investment Opportunities and Sector Allocation - Four major themes are highlighted for investment opportunities: 1. The manufacturing sector's competition for global pricing power, with a focus on industries such as non-ferrous metals, chemicals, and new energy, which can convert market share advantages into pricing power and profit margin increases 2. The globalization of Chinese enterprises, significantly expanding market capitalization and profit growth potential, with key industries including machinery, innovative pharmaceuticals, electric equipment, and military industry 3. The continuation of the technology trend, particularly in AI, which is expected to further expand its commercial applications and enhance the competitive advantages of Chinese companies, focusing on sectors like semiconductors, computing power, edge hardware, and AI applications 4. The potential for unexpected recovery in domestic demand, where although the outlook for domestic demand-related sectors is generally moderate, there exists significant room for recovery and valuation elasticity [2]

Core Insights - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] Industry Outlook - The pharmaceutical and biotechnology industry in China is expected to officially enter a new era of innovative drugs in 2026, with innovative drugs gradually dominating the market [1] - The combination of medical insurance and commercial insurance is anticipated to open up long-term payment space for innovative drugs, supporting their continued growth [1] Domestic Focus - In 2026, there will be increased attention on the launch rhythm of innovative drugs, the leading status of popular target layouts, the competitiveness of the market, and the outcomes of key clinical data [1] International Focus - With the normalization of business development (BD) transactions, there will be a focus on the improvement of cash flow from upfront payments and the overseas clinical progress of authorized projects [1] - The performance of overseas launched products will also be closely monitored [1] Sector Performance - The CXO and upstream scientific reagent sectors within the innovative drug industry chain are expected to maintain good growth momentum due to the rapid development of innovative drugs [1] - Recent sentiment in the innovative drug sector has cooled, but with ongoing BD transactions, the sector's prosperity is expected to be sustainable [1] - The trend of "innovation + internationalization" in the innovative drug industry remains unchanged, with improved fundamentals observed in the industry chain [1]